5-fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: An eastern cooperative oncology group phase II study (E1889)

Jordan D. Berlin, Kathleen J. Propert, Donald Trump, George Wilding, Gary Hudes, John Glick, Patrick Burch, Alan Keller, Patrick Loehrer

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

This report is a multi-institutional phase II study designed to obtain the response rate, survival, and toxicity profile for patients having hormone-refractory prostate cancer. Patients who had bidimensionally measurable prostate carcinoma in first or second remission after previous hormonal therapy but no history of chemotherapy were eligible. Patients were treated with leucovorin, 20 mg/m2 intravenously, followed by 5-fluorouracil (5-FU), 425 mg/m2 intravenously daily for 5 days, with cycles repeated every 28 days. Of 38 eligible patients, 3 (7.9%) had partial responses to therapy and 20 (52.6%) had stable disease. Median survival was 11.6 months for all 38 patients and median time to progression was 4.4 months. Most of the serious side effects were gastrointestinal or hematologic and overall, 23 of 38 patients (60.5%) experienced at least one grade 3 or 4 treatment-related toxicity of any type, as measured by the National Cancer Institute common toxicity criteria. Five patients (13.2%) withdrew from the study because of adverse reactions from chemotherapy. We conclude that treatment of hormone- refractory prostate cancer patients with 5-FU and leucovorin chemotherapy produced few responses at the cost of significant side effects. Further investigation of this combination is not warranted in this setting.

Original languageEnglish
Pages (from-to)171-176
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume21
Issue number2
DOIs
StatePublished - Apr 1998

Fingerprint

Leucovorin
Fluorouracil
Prostatic Neoplasms
Hormones
Therapeutics
Drug Therapy
National Cancer Institute (U.S.)
Prostate
Survival Rate
Carcinoma
Survival

Keywords

  • 5-Fluorouracil
  • Chemotherapy
  • Leucovorin
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

5-fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer : An eastern cooperative oncology group phase II study (E1889). / Berlin, Jordan D.; Propert, Kathleen J.; Trump, Donald; Wilding, George; Hudes, Gary; Glick, John; Burch, Patrick; Keller, Alan; Loehrer, Patrick.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 21, No. 2, 04.1998, p. 171-176.

Research output: Contribution to journalArticle

Berlin, Jordan D. ; Propert, Kathleen J. ; Trump, Donald ; Wilding, George ; Hudes, Gary ; Glick, John ; Burch, Patrick ; Keller, Alan ; Loehrer, Patrick. / 5-fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer : An eastern cooperative oncology group phase II study (E1889). In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1998 ; Vol. 21, No. 2. pp. 171-176.
@article{15714e51c211408694b2e09b1313a4d9,
title = "5-fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: An eastern cooperative oncology group phase II study (E1889)",
abstract = "This report is a multi-institutional phase II study designed to obtain the response rate, survival, and toxicity profile for patients having hormone-refractory prostate cancer. Patients who had bidimensionally measurable prostate carcinoma in first or second remission after previous hormonal therapy but no history of chemotherapy were eligible. Patients were treated with leucovorin, 20 mg/m2 intravenously, followed by 5-fluorouracil (5-FU), 425 mg/m2 intravenously daily for 5 days, with cycles repeated every 28 days. Of 38 eligible patients, 3 (7.9{\%}) had partial responses to therapy and 20 (52.6{\%}) had stable disease. Median survival was 11.6 months for all 38 patients and median time to progression was 4.4 months. Most of the serious side effects were gastrointestinal or hematologic and overall, 23 of 38 patients (60.5{\%}) experienced at least one grade 3 or 4 treatment-related toxicity of any type, as measured by the National Cancer Institute common toxicity criteria. Five patients (13.2{\%}) withdrew from the study because of adverse reactions from chemotherapy. We conclude that treatment of hormone- refractory prostate cancer patients with 5-FU and leucovorin chemotherapy produced few responses at the cost of significant side effects. Further investigation of this combination is not warranted in this setting.",
keywords = "5-Fluorouracil, Chemotherapy, Leucovorin, Prostate cancer",
author = "Berlin, {Jordan D.} and Propert, {Kathleen J.} and Donald Trump and George Wilding and Gary Hudes and John Glick and Patrick Burch and Alan Keller and Patrick Loehrer",
year = "1998",
month = "4",
doi = "10.1097/00000421-199804000-00016",
language = "English",
volume = "21",
pages = "171--176",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - 5-fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer

T2 - An eastern cooperative oncology group phase II study (E1889)

AU - Berlin, Jordan D.

AU - Propert, Kathleen J.

AU - Trump, Donald

AU - Wilding, George

AU - Hudes, Gary

AU - Glick, John

AU - Burch, Patrick

AU - Keller, Alan

AU - Loehrer, Patrick

PY - 1998/4

Y1 - 1998/4

N2 - This report is a multi-institutional phase II study designed to obtain the response rate, survival, and toxicity profile for patients having hormone-refractory prostate cancer. Patients who had bidimensionally measurable prostate carcinoma in first or second remission after previous hormonal therapy but no history of chemotherapy were eligible. Patients were treated with leucovorin, 20 mg/m2 intravenously, followed by 5-fluorouracil (5-FU), 425 mg/m2 intravenously daily for 5 days, with cycles repeated every 28 days. Of 38 eligible patients, 3 (7.9%) had partial responses to therapy and 20 (52.6%) had stable disease. Median survival was 11.6 months for all 38 patients and median time to progression was 4.4 months. Most of the serious side effects were gastrointestinal or hematologic and overall, 23 of 38 patients (60.5%) experienced at least one grade 3 or 4 treatment-related toxicity of any type, as measured by the National Cancer Institute common toxicity criteria. Five patients (13.2%) withdrew from the study because of adverse reactions from chemotherapy. We conclude that treatment of hormone- refractory prostate cancer patients with 5-FU and leucovorin chemotherapy produced few responses at the cost of significant side effects. Further investigation of this combination is not warranted in this setting.

AB - This report is a multi-institutional phase II study designed to obtain the response rate, survival, and toxicity profile for patients having hormone-refractory prostate cancer. Patients who had bidimensionally measurable prostate carcinoma in first or second remission after previous hormonal therapy but no history of chemotherapy were eligible. Patients were treated with leucovorin, 20 mg/m2 intravenously, followed by 5-fluorouracil (5-FU), 425 mg/m2 intravenously daily for 5 days, with cycles repeated every 28 days. Of 38 eligible patients, 3 (7.9%) had partial responses to therapy and 20 (52.6%) had stable disease. Median survival was 11.6 months for all 38 patients and median time to progression was 4.4 months. Most of the serious side effects were gastrointestinal or hematologic and overall, 23 of 38 patients (60.5%) experienced at least one grade 3 or 4 treatment-related toxicity of any type, as measured by the National Cancer Institute common toxicity criteria. Five patients (13.2%) withdrew from the study because of adverse reactions from chemotherapy. We conclude that treatment of hormone- refractory prostate cancer patients with 5-FU and leucovorin chemotherapy produced few responses at the cost of significant side effects. Further investigation of this combination is not warranted in this setting.

KW - 5-Fluorouracil

KW - Chemotherapy

KW - Leucovorin

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0031922729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031922729&partnerID=8YFLogxK

U2 - 10.1097/00000421-199804000-00016

DO - 10.1097/00000421-199804000-00016

M3 - Article

C2 - 9537206

AN - SCOPUS:0031922729

VL - 21

SP - 171

EP - 176

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -